Quarterly ResultAug 13, 2026, 04:04 PM
Aktis Oncology Advances Clinical Pipeline; Q2 Net Loss $24.1M
AI Summary
Aktis Oncology reported Q2 2026 financial results and significant clinical advancements. The company presented positive first-in-human data for AKY-2519, initiated a Phase 1b trial for AKY-2519 in mCRPC, and is enrolling patients in a Phase 1b trial for AKY-1189. Financially, Aktis reported a net loss of $24.1 million, with cash reserves of $517.3 million expected to fund operations into 2029.
Key Highlights
- Cash, cash equivalents, and marketable securities were $517.3 million as of June 30, 2026.
- Collaboration revenue increased to $3.4 million in Q2 2026 from $1.6 million in Q2 2025.
- Net loss for Q2 2026 was $24.1 million, compared to $18.1 million in Q2 2025.
- R&D expenses rose to $25.3 million in Q2 2026 from $18.6 million in Q2 2025.
- Presented first-in-human clinical imaging and dosimetry data for AKY-2519 at ASCO.
- Initiated Phase 1b trial of AKY-2519 in metastatic castration-resistant prostate cancer.
- On track to initiate Phase 1b trial of AKY-2519 in other B7-H3 expressing solid tumors in H2 2026.
- Preliminary data from AKY-1189 Phase 1b trial expected in Q1 2027.
Price Impact
More from AKTS